|
rs1264352930
|
APOA1;APOA1-AS
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
Delayed postprandial retinyl palmitate and squalene removal in a patient heterozygous for apolipoprotein A-IFIN mutation (Leu 159-->Arg) and low HDL cholesterol level without coronary artery disease.
|
9125314 |
1996 |
|
rs1384889210
|
APOA1;APOA1-AS
|
Coronary Arteriosclerosis
|
|
0.010 |
GeneticVariation |
BEFREE |
Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease.
|
8840853 |
1996 |
|
rs1384889210
|
APOA1;APOA1-AS
|
Coronary heart disease
|
|
0.010 |
GeneticVariation |
BEFREE |
Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease.
|
8840853 |
1996 |
|
rs1384889210
|
APOA1;APOA1-AS
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease.
|
8840853 |
1996 |
|
rs387906571
|
APOA1;APOA1-AS
|
Amyloidosis, Primary Cutaneous
|
|
0.010 |
GeneticVariation |
BEFREE |
A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis.
|
10198255 |
1999 |
|
rs1264352930
|
APOA1;APOA1-AS
|
Hypoalphalipoproteinemias
|
|
0.010 |
GeneticVariation |
BEFREE |
We have devised a combined in vivo, ex vivo, and in vitro approach to elucidate the mechanism(s) responsible for the hypoalphalipoproteinemia in heterozygous carriers of a naturally occurring apolipoprotein A-I (apoA-I) variant (Leu(159) to Arg) known as apoA-I Finland (apoA-I(FIN)).
|
11292828 |
2001 |
|
rs369066087
|
APOA1;APOA1-AS
|
Myocardial Infarction
|
|
0.010 |
GeneticVariation |
BEFREE |
The ApoA1 T84C polymorphism is an important marker for the HDL-C level and may be a new risk marker for MI in Japanese.
|
15258834 |
2004 |
|
rs121912717
|
APOA1;APOA1-AS
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
No association was found between the G664A polymorphism and CAD in our population.
|
16721833 |
2006 |
|
rs777407596
|
APOA1;APOA1-AS
|
Cardiovascular Diseases
|
|
0.010 |
GeneticVariation |
BEFREE |
For this purpose, we assayed -1.131T>C and c.56C>G polymorphisms for 279 subjects divided into three groups: a control group, a metabolic syndrome group and a cardiovascular disease group.
|
17635078 |
2007 |
|
rs670
|
APOA1;APOA1-AS
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
The minor 'A' allele of the APOAI rs670 polymorphism was found to be not associated with CAD, contrary to previous reports.
|
18179799 |
2008 |
|
rs12721026
|
APOA1;APOA1-AS
|
Obesity
|
|
0.010 |
GeneticVariation |
BEFREE |
The GC haplotype, which is composed of the G-allele of rs12721026 and the C-allele of rs1729408, was significantly associated with obesity (P = 0.028), with higher glycated hemoglobin (P = 0.006), and fasting glucose (P = 0.0003) compared to the TT haplotype, which includes the wild-type alleles of both polymorphisms.
|
20480398 |
2010 |
|
rs670
|
APOA1;APOA1-AS
|
Dyslipidemias
|
|
0.030 |
GeneticVariation |
BEFREE |
ApoB rs512535 and ApoA1 rs670 major G allele homozygotes had increased MetS risk (OR 1.65 [CI 1.24, 2.20], P = 0.0006; OR 1.42 [CI 1.08, 1.87], P = 0.013), which may be, partly, explained by their increased abdominal obesity and impaired insulin sensitivity (P<0.05) but not dyslipidemia.
|
21122859 |
2011 |
|
rs670
|
APOA1;APOA1-AS
|
Metabolic Syndrome X
|
|
0.020 |
GeneticVariation |
BEFREE |
ApoB rs512535 and ApoA1 rs670 may influence MetS risk.
|
21122859 |
2011 |
|
rs670
|
APOA1;APOA1-AS
|
Obesity
|
|
0.020 |
GeneticVariation |
BEFREE |
ApoB rs512535 and ApoA1 rs670 major G allele homozygotes had increased MetS risk (OR 1.65 [CI 1.24, 2.20], P = 0.0006; OR 1.42 [CI 1.08, 1.87], P = 0.013), which may be, partly, explained by their increased abdominal obesity and impaired insulin sensitivity (P<0.05) but not dyslipidemia.
|
21122859 |
2011 |
|
rs2070665
|
APOA1;APOA1-AS
|
Serum albumin measurement
|
|
0.700 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies multiple loci influencing human serum metabolite levels.
|
22286219 |
2012 |
|
rs5072
|
APOA1;APOA1-AS
|
Serum total cholesterol measurement
|
|
0.700 |
GeneticVariation |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
rs5072
|
APOA1;APOA1-AS
|
Serum albumin measurement
|
|
0.700 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies multiple loci influencing human serum metabolite levels.
|
22286219 |
2012 |
|
rs5072
|
APOA1;APOA1-AS
|
Triglycerides measurement
|
|
0.700 |
GeneticVariation |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
rs1264352930
|
APOA1;APOA1-AS
|
Atherosclerosis
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, large HDL-like particles containing apoE and apoA-I(L159R) contribute rather than protect against atherosclerosis, possibly through defective efflux properties and their potential for aggregation at their site of interaction in the aorta.
|
21944998 |
2012 |
|
rs1264352930
|
APOA1;APOA1-AS
|
Arteriosclerosis
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, large HDL-like particles containing apoE and apoA-I(L159R) contribute rather than protect against atherosclerosis, possibly through defective efflux properties and their potential for aggregation at their site of interaction in the aorta.
|
21944998 |
2012 |
|
rs777407596
|
APOA1;APOA1-AS
|
Hypertriglyceridemia
|
|
0.010 |
GeneticVariation |
BEFREE |
Various studies have identified a number of common (APOA5 c.56C>G; p.S19W; rs 3135506 ) and rare variants in the APOA5 gene in individuals with hypertriglyceridemia.
|
22914599 |
2012 |
|
rs12721025
|
APOA1;APOA1-AS
|
Pyloric Stenosis, Hypertrophic
|
A |
0.800 |
GeneticVariation |
GWASDB |
Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis.
|
23989729 |
2013 |
|
rs12721025
|
APOA1;APOA1-AS
|
Pyloric Stenosis, Hypertrophic
|
A |
0.800 |
GeneticVariation |
GWASCAT |
Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis.
|
23989729 |
2013 |
|
rs670
|
APOA1;APOA1-AS
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings suggest that APOA1 rs670 indicate a post-surgery risk of breast cancer disease progression, and that carriers of this SNP may benefit from more advanced disease monitoring and therapy regimens than the current regular standards.
|
23829168 |
2013 |
|
rs670
|
APOA1;APOA1-AS
|
Recurrent tumor
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, rs670 A/A carrying patients had higher risks in both tumor recurrence (HR=3.12, 95% CI=1.29-7.56, p=0.012) and mortality (HR=4.36, 95% CI=1.52-12.47, p=0.006) than patients with no A alleles after adjustments for associated baseline parameters.
|
23829168 |
2013 |